Добірка наукової літератури з теми "Proprotein convertase 1 – génétique"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Proprotein convertase 1 – génétique".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Proprotein convertase 1 – génétique":
Kumar, Gurinder, Rajendran Nair, and Aman P. S. Sohal. "Proprotein Convertase 1/3 Deficiency." Indian Journal of Pediatrics 85, no. 4 (September 30, 2017): 320–21. http://dx.doi.org/10.1007/s12098-017-2479-x.
Pasquato, Antonella, Philomena Pullikotil, Marie-Claude Asselin, Manuela Vacatello, Livio Paolillo, Francesca Ghezzo, Federica Basso, Carlo Di Bello, Monica Dettin, and Nabil G. Seidah. "The Proprotein Convertase SKI-1/S1P." Journal of Biological Chemistry 281, no. 33 (June 21, 2006): 23471–81. http://dx.doi.org/10.1074/jbc.m513675200.
Pullikotil, Philomena, Suzanne Benjannet, Janice Mayne, and Nabil G. Seidah. "The Proprotein Convertase SKI-1/S1P." Journal of Biological Chemistry 282, no. 37 (July 10, 2007): 27402–13. http://dx.doi.org/10.1074/jbc.m703200200.
Yana, Ikuo, and Stephen J. Weiss. "Regulation of Membrane Type-1 Matrix Metalloproteinase Activation by Proprotein Convertases." Molecular Biology of the Cell 11, no. 7 (July 2000): 2387–401. http://dx.doi.org/10.1091/mbc.11.7.2387.
Icimoto, Marcelo Y., Nilana M. Barros, Juliana C. Ferreira, Marcelo F. Marcondes, Douglas Andrade, Mauricio F. Machado, Maria A. Juliano, Wagner A. Júdice, Luiz Juliano, and Vitor Oliveira. "Hysteretic Behavior of Proprotein Convertase 1/3 (PC1/3)." PLoS ONE 6, no. 9 (September 15, 2011): e24545. http://dx.doi.org/10.1371/journal.pone.0024545.
Oral, H. "Proprotein Convertase 1/3 Deficiency with Pelvic Ewing Sarcoma." Acta Endocrinologica (Bucharest) 18, no. 4 (2022): 508–11. http://dx.doi.org/10.4183/aeb.2022.508.
Jirholt, Pernilla, Martin Adiels, and Jan Borén. "How Does Mutant Proprotein Convertase Neural Apoptosis-Regulated Convertase 1 Induce Autosomal Dominant Hypercholesterolemia?" Arteriosclerosis, Thrombosis, and Vascular Biology 24, no. 8 (August 2004): 1334–36. http://dx.doi.org/10.1161/01.atv.0000133682.97348.ff.
Seidah, N. G., S. Benjannet, L. Wickham, J. Marcinkiewicz, S. B. Jasmin, S. Stifani, A. Basak, A. Prat, and M. Chretien. "The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation." Proceedings of the National Academy of Sciences 100, no. 3 (January 27, 2003): 928–33. http://dx.doi.org/10.1073/pnas.0335507100.
Lee, Y. C., A. B. Damholt, N. Billestrup, T. Kisbye, P. Galante, B. Michelsen, H. Kofod, and J. H. Nielsen. "Developmental expression of proprotein convertase 1/3 in the rat." Molecular and Cellular Endocrinology 155, no. 1-2 (September 1999): 27–35. http://dx.doi.org/10.1016/s0303-7207(99)00119-7.
Ahmed, Amna Basheer M., and Badr M. Rasheed Alsaleem. "Enteroendocrine Dysfunction in Two Saudi Sisters." Case Reports in Gastroenterology 15, no. 1 (March 4, 2021): 290–95. http://dx.doi.org/10.1159/000511761.
Дисертації з теми "Proprotein convertase 1 – génétique":
Guerardel, Audrey. "Analyse de deux gènes candidats physiologiques et positionnels de l'obésité humaine CART et PCSK1." Lille 2, 2005. http://www.theses.fr/2005LIL2S012.
Common obesity is a multifactorial disease, whose recent increase, is related to the modernization of life. This epidemic is the consequence of a physical inactivity and an unlimited access to over-nutrition and consumption of caloric food. Nevertheless, many familial studies and the identification of monogenic forms of obesity indicate that genetic factors are also involved. All determinants of the polygenic forms are still unknown, recent studies show the role of genes in the signalling of insulin (ENPP1) and metabolic pathways of neurotransmitters (GABA, serotonin) which would predispose to obesity in a sedentary, high calorie lifestyle. The identification of genetic factors in the polygenic diseases such as obesity is assessed by direct studies of physiological genes and by indirect analyses with positional candidate genes located in chromosomal regions of linkage to phenotype traits. Two genome wide-scans on French Caucasian families show the importance of the locus 5cen-q. Among many genes located in this region ; CART (5q12-q13) and PCSK1 (5q15-q21) genes are expressed in the central nervous system (principally in the hypothalamus) and are involved in the control of food intake and the regulation of energy homeostasis. The analysis of a 5,4 Kb region of the CART gene (Cocaine and Amphetamine Regulated Transcript), including the promoter, 3 exons, introns and the 3'UTR, resulted in the identification of a promoter SNP (SNP-3608T>C) which is associated with the polygenic obesity. In a general population, this polymorphism is also associated, with subfractions of plasma cholesterol and apolipoproteins which suggests that the CART gene maybe implicated in lipid metabolism and atherogenesis. Within a Danish study of menopausal women, the SNP-3608T>C was shown to effect remodelling of the bone mass (on arm BMD). PCSK1 (Proprotein Convertase Subtilisin/kexin type 1) Gene code for a neuroendocrine member of the family of subtilisin-like proprotein convertases and is important for the maturation of pro-hormones and neuropeptides precursors such as the proinsulin and POMC. PCSK1 gene mutations are responsible for a number of rare monogenic forms of severe obesity. The analysis of this gene in a polygenic context enabled the identification of frequent mutations including a non-synonymous exonic variant which is associated with adult and/or childhood polygenic obesity. The genetic approach validates physiological hypotheses and improves current understanding of metabolic pathways, and suggests a pleiotropic effect of the CART gene and that the CART and PCSK1 genes are implicated in polygenic obesity
Choquet, Hélène. "Contribution du gène PCSK1 aux formes monogéniques et polygéniques d’obésité." Thesis, Lille 2, 2010. http://www.theses.fr/2010LIL2S012/document.
Four whole genome studies basing on positional cloning approach revealed a region ofchromosome 5q linked to traits related to obesity, this region contained the gene coding forthe prohormone convertase 1 named PCSK1. Pc1 mutation in mice has been associated withobesity, hyperphagia and increased metabolic efficiency. In human, PCSK1 deficiency is amonogenic form of obesity. The first case of complete PCSK1 deficiency has been identifiedin 1997 and since two other cases were discovered. Deleterious PCSK1 mutations carrierswere either homozygous or compound heterozygous and presented severe phenotypes, such asobesity, intestinal troubles and endocrine disorders. Surprisingly, the family members whowere heterozygous for these mutations appeared clinically unaffected. Overall of these studieshighlighted PCSK1 as a candidate gene for obesity.We have therefore decided to assess the contribution of PCSK1 gene to polygenicobesity risk. To assess the contribution of PCSK1 to polygenic obesity risk, we genotyped tagsingle nucleotide polymorphisms in a total of 13,659 European individuals from eightindependent case-control or family-based cohorts. The non-synonymous variants rs6232,encoding N221D, and cluster rs6234-rs6235, encoding the Q665E-S690T pair, wereconsistently associated with obesity in adults and children (P=7.27 x 10-8 and P=2.31 x 10-12,respectively). Functional analysis revealed a significant impairment of the N221D mutant onPC1/3 protein catalytic activity.In continuity of this study we decided to assess the involvement of PCSK1 gene inmonogenic obesity, knowing that only three cases of complete PCSK1 deficiency have beenreported up to now. The objectives of this study were to evaluate the prevalence of rarePCSK1 mutations contributing to human obesity and to investigate the mode of inheritance ofobesity in the context of PCSK1 deficiency. We sequenced exons of the PCSK1 gene in 845non-consanguineous extremely obese subjects of European origin and we identified eightnovel PCSK1 non-synonymous mutations in eight carriers, all heterozygous. Wecharacterized the functional consequences of the detected mutations on PC1/3 protein and wefound that 62.5% of mutations detected were predicted to be deleterious in silico and werevealed that 87.5% of mutations had an effect on the autoactivation or on the enzymaticactivity of PC1/3 in vitro. In order to estimate the degree of penetrance for the sevenpathogenic mutations, we genotyped 6,060 obese and 6,274 lean subjects. We assessed a 6-fold enrichment of these PCSK1 mutations in obese subjects (P = 0.007). We provided thefirst evidence of an increased obesity risk in heterozygous carriers of loss of functionmutations in PCSK1 gene, confirming a co-dominant mode of transmission of obesity withincomplete penetrance for this gene. The penetrance of obesity was estimated to 54.5% for108heterozygous carriers of deleterious PCSK1 mutations. Partial PCSK1 deficiency mightexplain ~ 0.83% of extreme obesity.To conclude, in addition of the syndromic forms of obesity due to a complete PCSK1deficiency, we provided the strong evidence of the contribution of common non-synonymousvariants in obesity risk and we highlighted that a partial PCSK1 deficiency is associated withan increased risk of obesity
Folon, Lise. "Étude de l'impact des variants génétiques rares sur l'obésité monogénique." Electronic Thesis or Diss., Université de Lille (2022-....), 2023. https://pepite-depot.univ-lille.fr/ToutIDP/EDBSL/2023/2023ULILS059.pdf.
Obesity is a complex multifactorial disease with a strong genetic component. Unlike common obesity, which is a polygenic disease, monogenic forms of obesity are caused by a single rare genetic variant with a strong and deleterious effect. These monogenic forms are rare, early-onset and generally very severe, affecting around 5% of individuals with obesity. Most rare mutations associated with monogenic obesity are found in genes within the leptin-melanocortin pathway, which is crucial for the regulation of food intake. Identifying these genes is crucial for understanding the pathophysiology of obesity and developing new treatments.I initially studied rare heterozygous variants of the PCSK1 gene, which encodes the prohormone convertase 1 (PC1/3) enzyme. PC1/3 is involved in the leptin-melanocortin pathway. Biallelic mutations in PCSK1 cause early-onset obesity with severe endocrinopathy. Patients with PCSK1 deficiency (heterozygous or homozygous) can now be treated with setmelanotide injections to promote weight loss. However, the impact of rare heterozygous variants of PCSK1 on obesity and their relevance in precision medicine are still not well-defined. In the RaDiO study, which included 9,320 participants, 65 rare heterozygous variants of PCSK1 were identified and assessed in vitro. These variants were classified into five groups based on the severity of their impact on the enzymatic activity of PC1/3. Association analysis results revealed that rare variants inducing a complete loss of function significantly increased the risk of obesity and body mass index (BMI), whereas variants in other groups with partial or neutral effects on PC1/3 activity had no impact on adiposity. We observed that in silico prediction tools were unreliable in detecting mutations leading to a complete loss of function.Subsequently, I focused on rare variants of the DYRK1B gene. Although this gene is not directly involved in the leptin-melanocortin pathway, pathogenic variants of DYRK1B have been described in several patients with central obesity, type 2 diabetes (T2D), and coronary artery disease. However, the impact of rare DYRK1B variants has not been assessed on a large scale. In the RaDiO study, which included 9,353 participants, 65 rare variants in DYRK1B were detected. Following in vitro analysis of each variant, we identified 20 pathogenic or likely pathogenic variants (P/LP) according to the criteria of the American College of Medical Genetics and Genomics. Among these P/LP variants, six showed an effect leading to a complete loss of function of DYRK1B (P/LP-full). Association analyses showed that P/LP-full variants of DYRK1B were strongly associated with increased BMI and fasting glucose levels, as well as a heightened risk of obesity and T2D, whereas P/LP variants had only a modest effect on adiposity and no impact on glucose homeostasis.In conclusion, the use of functional genetics has demonstrated that only heterozygous variants of PCSK1 and DYRK1B with a complete loss of function cause monogenic obesity. For DYRK1B, obesity is additionally associated with T2D. These results underscore the critical significance of assessing the functional impact of mutations in vitro for genetic diagnosis and the potential selection of appropriate treatments. We have demonstrated that in silico prediction tests are currently not precise enough
Rabah, Nadia. "Production et caractérisation de la prohormone convertase 13." Thesis, McGill University, 2007. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=103282.
The structural characterisation of the enzyme is compromised by the difficulty in producing a sufficient amount of recombinant PC1/3. In this thesis it is clearly demonstrated that the production of PC1/3 using Baculovirus technology can be greatly improved by modifying the expression vector in insect cells (Spodoptera frugiperda). In addition, the intracoelemic injection of insect larvae (Tricoplusia ni) with the Baculovirus encoding the recombinant PC1/3 is shown to be a very efficient method for the production of a large amount of prohormone convertases.
It was previously demonstrated that the propeptide is essential for the folding of the enzyme and act as a tight binding inhibitor of the enzyme until the latter reaches the appropriate compartment for substrate cleavage. To assess the role of certain residues within the propeptide in the inhibition of the cognate enzyme, a mutational analysis by alanine scan was conducted. The results demonstrate that the substitution of a single amino acid can affect markedly the inhibition behavior, potency and selectivity of the propeptide towards the enzyme. Moreover, this mutational analysis allowed the first experimental mapping of the sequence involved in propeptide degradation once its function is achieved.
However, PC1/3 also possesses a C-terminal domain which must also be cleaved to allow the full activation of the enzyme. Previous studies showed that this domain is implicated in the sorting of the enzyme to secretory granules. In addition, over expression experiments showed that the C-terminal domain can inhibit the cleavage of certain substrates by PC1/3. The results, presented here, suggest that the CT-peptide acts as a non-essential activator of PC1/3, in vitro, which adds a supplementary level of complexity to the activation process of the enzyme.
Finally, based upon our results, it can be proposed that PC1/3 is a very complex enzyme capable of controlling its enzymatic activity through the coordinate action of its various domains. This exceptional mode of self-regulation is unique among all protease families.
Tzimas, George N. "Proprotein convertase 1 and 2 profiles in human liver colorectal metastases." Thesis, McGill University, 2004. http://digitool.Library.McGill.CA:80/R/?func=dbin-jump-full&object_id=80889.
Mohottalage, R. A. M. Dayani R. "Modulators of proprotein convertase, Subtilisin Kexin Isozyme-1 (SKI-1) Site 1 Protease (SIP): Design, synthesis and in vitro evaluation." Thesis, University of Ottawa (Canada), 2009. http://hdl.handle.net/10393/28252.
Panet, François. "L’implication de la proprotéine convertase PACE4 dans le cancer du sein." Mémoire, Université de Sherbrooke, 2017. http://hdl.handle.net/11143/11085.
Abstract: Breast cancer is the most frequent and deadly malignancy in women worldwide. Despite national screening prog rams combined with new treatments relapse rate remain high and new therapies are needed. Even in industrialized country like Canada, it is still the second most deadly cancer in women. From previous work, we identified PACE4, a member of the proprotein convertases (PCs) family of endoproteases, as a novel therapeutic target in prostate cancer. In the present study, we examined whether PACE4 could also be a potential target in breast cancer. In clinical samples of breast adenocarcinoma, we observed a specific overexpression of PACE4 in the estrogen-receptor-positive (ER+) subtype. We therefore looked for a breast cancer cell line model which would be representative and thus focused on ZR-75-1 since it both expresses PACE4 and is estrogen-receptor-positive. We compared stable knockdowns of furin, PACE4 and PC7 in the estrogen-receptor-positive cell line ZR-75-1 to evaluate their respective contribution to cell growth and tumor progression. PACE4 was found to be the only PC displaying a decrease in cell growth. The impact of PACE4 on tumor growth was also confirmed in vivo with xenograft of the ZR-75-1 cell line in athymic nude mice. PACE4 specific peptide-based inhibitors (C23 and Multi-Leu) were tested and shown to decrease prolife ration of ZR-75-1 cells in cell-based assays. We also confirmed that PACE4 expression was necessary for its specific peptide-based inhibitors to penetrates in the cell using a radiolabeled Multi-Leu peptide. Moreover, the systemic administration of C23 had a potent effect on tumor growth on xenografts of the ZR-75-1 cell line. Interestingly, PACE4-silencing and systemic administration of the PACE4 inhibitor C23 resulted in similar slowed tumor growth in vivo. Furthermore, these tumors demonstrated lower Ki67 proliferative indices with increased cell quiescence assessed with p27 KIP1 and p21 Waf1/Cip1 biomarkers. To conclude, PACE4-silencing and systemic administration of a PACE4 inhibitor result in hindered tumor progression and slower cellular proliferation. Our results suggest that PACE4 is a promising target for estrogen-receptor-positive breast cancer.
El, Bitar Sandy. "Genetic causes of cardiovascular diseases : special focus on familial hypercholesterolemia and thoracic aortic aneurysms." Thesis, Sorbonne Paris Cité, 2018. https://theses.md.univ-paris-diderot.fr/EL_BITAR_Sandy_2_va_20180403.pdf.
The identification of new actors involved in cardiovascular diseases (CVD) allows a better understanding of their pathophysiology. The objective of our studies was to investigate the genetic causes of CVD and their risk factors with a special focus on Familial Hypercholesterolemia (FH) and Thoracic Aortic Aneurysm and Dissection (TAAD).The first part of this work consisted on studying the genetic causes of ADH in French probands. Through an exome sequencing approach, we identified the p.(Arg50Gln) and the p.(Ala3396Thr) variations in the APOB gene, which occur in a region not routinely sequenced when diagnosing FH by Sanger sequencing. In addition, we reported the first compound heterozygote with the p.(Ala3396Thr) mutation of APOB and the p.(Arg96Cys) mutation of PCSK9 and we proved by functional assays that the p.(Arg96Cys) variation of PCSK9 leads to increased LDL receptor degradation. A second part of this work consisted on studying the genetic defect in patients who suffer from familial TAAD. After exclusion of the known genes associated to the disease, exome sequencing results suggested that THSD4, also known as ADAMTSL6, might be a potential candidate gene of TAAD. We demonstrated that THSD4 is a new gene involved in the pathogenesis of the disease. Human variations in this gene are associated with TAAD. Functional studies showed that missense variants of this gene lead to a decrease in levels of intracellular THSD4 and also affect the fibrillin-1 microfibril assembly in the extracellular matrix. THSD4 levels in plasma measured by an ELISA assay suggested that THSD4 might be a potential biomarker for aortic aneurysm of different etiologies.We conducted studies on FH in Lebanon and we identified variations in the LDLR and the LDLRAP1 genes, highlighting the high incidence of heterozygous and homozygous FH in the Lebanese population. In addition, we initiated genetic studies on TAAD in order to establish the mutational spectrum of this disease in Lebanon. These results demonstrate the importance of genetic strategies applied on familial studies to discover new genes responsible of CVD, or new mutations in already known genes. This can lead to a better understanding of the pathophysiology of complex diseases, a better diagnosis, and the implementation of better strategies for adequate clinical management
Durand, Loreleï. "PC7 : une protéase sécrétoire énigmatique ayant une fonction de sheddase et un ciblage cellulaire unique." Thèse, 2019. http://hdl.handle.net/1866/22519.
Частини книг з теми "Proprotein convertase 1 – génétique":
Schomburg, Dietmar, and Dörte Stephan. "Proprotein convertase 1." In Enzyme Handbook 15, 769–72. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-58948-5_156.
Das, Soumik, Abilash Valsala Gopalakrishnan, C. George Priya Doss, and R. Gnanasambandan. "Proprotein Convertase 1/3 Deficiency." In Genetic Syndromes, 1–4. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-319-66816-1_1847-1.
Fu, YangXin, and Mark W. Nachtigal. "Analysis of Epigenetic Alterations to Proprotein Convertase Genes in Disease." In Methods in Molecular Biology, 231–45. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-204-5_12.
Chitramuthu, Babykumari P., and Hugh P. J. Bennett. "Use of Zebrafish and Knockdown Technology to Define Proprotein Convertase Activity." In Methods in Molecular Biology, 273–96. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-204-5_15.
Mbikay, Majambu, Marie-Laure Raffin-Sanson, Haidy Tadros, Francine Sirois, Nabil G. Seidah, and Michel Chrétien. "Testis-Specific Proprotein Convertase 4: Gene Structure, Optional Exons, and mRNA Isoforms." In Function of Somatic Cells in the Testis, 388–99. New York, NY: Springer New York, 1994. http://dx.doi.org/10.1007/978-1-4612-2638-3_25.
Basak, Ajoy, Andrew Chen, Swapan Majumdar, and Heather Palmer Smith. "In Vitro Assay for Protease Activity of Proprotein Convertase Subtilisin Kexins (PCSKs): An Overall Review of Existing and New Methodologies." In Methods in Molecular Biology, 127–53. Totowa, NJ: Humana Press, 2011. http://dx.doi.org/10.1007/978-1-61779-204-5_6.
Basak, Ajoy, Peter Koch, Marcel Dupelle, Francine Sirois, Michel Chrétien, Nabil G. Seidah, and Majambu Mbikay. "A Highly Selective Cell Permeable Peptide Inhibitor of Proprotein Convertase 1: Design, Synthesis and Biological Evaluation in Cellular PC1-Mediated Proteolysis." In Peptides: The Wave of the Future, 558–60. Dordrecht: Springer Netherlands, 2001. http://dx.doi.org/10.1007/978-94-010-0464-0_259.
Seidah, Nabil G. "Proprotein Convertase 1/3." In Handbook of Proteolytic Enzymes, 3286–90. Elsevier, 2013. http://dx.doi.org/10.1016/b978-0-12-382219-2.00726-2.
Thompson, Gilbert R. "Familial hypercholesterolaemia." In Oxford Textbook of Endocrinology and Diabetes, 1667–73. Oxford University Press, 2011. http://dx.doi.org/10.1093/med/9780199235292.003.1240.